Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Carbonxt Group - Appendix 4C (ASX:CG1)

To view the Quarterly cash flow report for entities subject to Listing Rule 4.7B, download the attached PDF.

Carbonxt Group - Trading Halt (ASX:CG1)

The securities of Carbonxt Group LImited ("CG1") will be placed in trading halt at the request of CG1, pending it releasing an announcement. Unless ASX decides otherwise, the securities wi...read more

CARETEQ Q4-FY22 Activities Report and Appendix 4C (ASX:CTQ)

Highlights: -- Careteq’s pipeline expands five-fold in 4QFY22 vs. the previous quarter with over 60 active leads across the US and Australia -- The Group is generating interest from a wide...read more

Carbonxt Group - Pause in Trading (ASX:CG1)

Trading in the securities of the entity will be temporarily paused pending a further announcement.

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 30...read more

Chimeric Therapeutics - Licenses viral vector technology from Penn for CDH17 (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has expanded its license agree...read more

Chimeric Therapeutics - A$30 million Equity Placement Agreement with L1 Capital (ASX:CHM)

* Initial Placement of A$500,000 in ordinary shares at A$0.10 each (being the closing bid price yesterday, 8 June 2022) and 15,000,000 unlisted options exercisable at A$0.255 each expiring 31 March ...read more

Carbonxt Group - Operations Update (ASX:CG1)

* Broad strength in US market conditions for Carbonxt’s core range of Powdered Activated Carbon (PAC) products * Supply constraints combined with inelastic demand contributing to price increa...read more

Carbonxt Group - March 2022 Quarterly Activities Report (ASX:CG1)

* Quarterly customer receipts of A$3.8m. However, a further $1.0m of receipts were subject to a logistics delay beyond our control and therefore revenue will be recognised in the next quarter. This ...read more

Carbonxt Group - Appendix 4C (ASX:CG1)

To view the Quarterly cash flow report for entities subject to Listing Rule 4.7B, download the attached PDF.

CARETEQ - 3Q-FY22 Activities Report & Appendix 4C (ASX:CTQ)

Highlights: * Careteq achieves several milestones in the quarter and advances on significant opportunities in Australia and North America, as highlighted in Careteq’s prospectus * Further ...read more

CARETEQ - Clarification of Appendix 3X & Appendix 3Y - M Simari (ASX:CTQ)

Careteq Limited (ASX: CTQ, “Careteq” or the “Group”) advises the following in relation to the Appendix 3X as lodged for Mr Simari on 11 January 2022: * The Appendix 3X was...read more

Chimeric Therapeutics - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:CHM)

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to provide a summary of its activities for the quarter ended 31...read more

Careteq & RMIT sign Research Collaboration Agreement (ASX:CTQ)

Highlights: * Leading Victorian university RMIT University will work with Careteq to develop new assistive living technology solutions to expand on Careteq’s proprietary Sofihub platform *...read more

Chimeric Therapeutics - Strategic manufacturing partnership with WuXi ATU (ASX:CHM)

* Global contract testing and manufacturing organization WuXi Advanced Therapies (WuXi ATU) to support Chimeric CAR T cell programs * Enables Chimeric to accelerate manufacturing readiness for its ...read more

Viewing: 121 - 135 of 200 Previous | Next